Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia

Recent progress in the development of potent vaccine adjuvants, clinically effective vaccine delivery systems, and agents that overcome tumor-induced immunosuppression strongly support the possibility that long-awaited effective therapeutic cancer vaccines are feasible.^1-4  Past cancer vaccine efforts have lacked efficacy that may stem from their focus on overexpressed or selectively expressed tumor-associated native antigens as vaccine targets that require overcoming the challenging hurdles of breaking central and peripheral tolerance while risking the generation of autoimmunity.^4-6  The rare examples of successful cancer vaccines in humans have targeted foreign pathogen-associated antigens⁷  or a mutated growth factor receptor⁸  or are idiotype vaccines derived from patient-specific rearranged immunoglobulins.⁹  These studies point to the importance of selecting immunogens distinct from self, where central/peripheral tolerance can be overcome and the risk of autoimmunity is minimal.

A hallmark of tumorigenesis is the accumulation of mutations in cancer cells. These mutations are found as both driver and passenger events¹⁰  and collectively provide an opportunity to specifically target tumor cells through the creation of tumor-specific novel immunogenic peptides (neoantigens). Neoantigens are generated from peptides encoded by gene alterations that are exclusively present in tumor but not normal tissue and therefore fulfill criteria as highly promising vaccine immunogens.^11,12  Several seminal studies have suggested the immunotherapeutic potential of neoantigens: (1) mice and humans can mount T-cell responses against mutated antigens^13,14 ; (2) mice are tumor protected by immunization with a single mutated peptide¹⁵ ; and (3) memory cytotoxic T lymphocyte (CTL) responses to mutated antigens are generated in patients with unexpected long-term survival or those who have undergone effective immunotherapy.^16-18  Neoantigens, however, have not been used for immunotherapy due to technical difficulties in their identification and preparation.¹³ 

Two recent technologies now overcome this limitation. First, massively parallel sequencing now readily provides the comprehensive identification of tens to thousands of somatic protein-coding mutations, which may create epitopes that can be recognized immunologically in an individual- and tumor-specific fashion.^10,19  Second, refinements in class I HLA prediction algorithms have enabled the reliable prediction of peptide binding for a broad range of class I HLA alleles.^20,21 

Herein, we report that putative neoantigens identified through sequential application of massively parallel sequencing followed by HLA-binding prediction are immunogenic in humans and can target malignant cells in a tumor-specific fashion. We focused on chronic lymphocytic leukemia (CLL), a common adult B-cell malignancy that remains largely incurable but is potentially immune responsive based on reports of its spontaneous regression and susceptibility to the graft-versus-leukemia effect.^22-24  We predicted candidate leukemia neoantigens from CLL DNA sequencing data^25,26  and then monitored neoantigen-specific T-cell responses in patients who had undergone allogeneic-hematopoietic stem cell transplantation (allo-HSCT).²⁷  Our approach provides a basis for designing truly personalized immunotherapeutic vaccines in humans.

Heparinized blood was obtained from patients enrolled on clinical research protocols at the Dana-Farber Cancer Institute (DFCI). All clinical protocols were approved by the DFCI Human Subjects Protection Committee. The study was conducted in accordance with the Declaration of Helsinki. Patient peripheral blood mononuclear cells (PBMCs) were isolated by Ficoll/Hypaque density-gradient centrifugation, cryopreserved with 10% dimethylsulfoxide, and stored in vapor-phase liquid nitrogen until time of analysis. HLA typing was performed by standard methods (supplemental Methods, available on the Blood Web site).

The somatic mutations detected in CLL have been previously reported,²⁶  whereas those for melanoma were obtained from the dbGaP database (phs000452.v1.p1) and for the 11 other cancers, through The Cancer Genome Atlas (Sage Bionetworks' Synapse resource; https://www.synapse.org/#!Synapse:syn1729383). We genotyped the HLA-A, -B, and -C loci in 2488 samples across 13 tumor types using a 2-stage likelihood-based approach (supplemental Methods; supplemental Table 9).

Major histocompatibility complex (MHC)-binding affinity was predicted across all possible 9- and 10-mer peptides generated from each somatic mutation and the corresponding wild-type peptides using NetMHCpan (v2.4). These tiled peptides were analyzed for their binding affinities (IC₅₀ nM) to each class I allele in the patients’ HLA profile. An IC₅₀ value of <150 nM was considered a predicted strong binder; between 150 and 500 nM, an intermediate to weak binder; and >500 nM, a nonbinder. We empirically confirmed predicted peptides binding to HLA molecules (IC₅₀ <500 nM) by competitive MHC class I allele-binding experiments.^28,29 

Autologous dendritic cells (DCs) were generated as previously described.²⁹  For some experiments, CD40L-Tri activated and expanded CD19⁺ B cells were used as antigen-presenting cells (APCs) (supplemental Methods).

To generate peptide-reactive T cells from CLL patients, immunomagnetically selected CD8⁺ T cells (10 million) from pre- and posttransplant PBMCs (CD8⁺ Microbeads; Miltenyi, Auburn, CA) were cultured with autologous peptide pool-pulsed DCs (at a 40:1 ratio). Subsequently, T cells were restimulated weekly (starting on day 7) with peptide-pulsed CD40L-Tri-activated irradiated B cells (at 4:1 ratio) either once more, to detect memory T-cell responses,^27,30  or thrice more, to detect naïve T-cell responses.³¹  All stimulations were conducted in complete medium supplemented with 10% fetal bovine serum and 5 to 10 ng/mL interleukin (IL)-7, IL-12, and IL-15 (R&D Systems, Minneapolis, MN). APCs were pulsed with peptide pools (10 μM/peptide/pool for 3 hours). T-cell specificity against peptide pools or autologous tumor was tested by interferon (IFN)-γ ELISPOT or a CD107a degranulation assay (supplemental Methods) 10 days following the last stimulation.

Two-way analysis of variance models were constructed for cytokine secretion measurements and included concentration and mutational status as fixed effects along with an interaction term as appropriate. P values for these models were adjusted for multiple comparisons post hoc (Tukey method). For other comparisons of continuous measures between groups, a Welch t test was used. All other P values reported are 2-sided and considered significant at the .05 level with appropriate adjustment for multiple comparisons. Analyses were performed in SAS, version 9.2.

We leveraged recent advances in sequencing technologies and peptide epitope prediction to establish a 2-step process for systematic discovery of candidate tumor-specific HLA-bound neoantigens. As depicted in Figure 1, we comprehensively identified tumor-specific nonsynonymous somatic mutations from DNA sequencing data of tumors (by whole-exome sequencing [WES] or whole-genome sequencing [WGS]) with matched sequencing of germ-line DNA.^32,33  Next, we used NetMHCpan, the well-validated prediction algorithm, to predict candidate tumor-specific mutated peptides with the potential to bind personal class I HLA proteins and hence for presentation to CD8⁺ T cells.^21,34  Finally, to identify a smaller number of epitopes for deeper investigation, we selected a subset of candidate peptide antigens based on experimental validation of their binding to HLA and expression of cognate mRNAs in autologous leukemia cells.

We applied this pipeline to a large dataset of 91 CLL samples,²⁶  previously characterized by WES or WGS. From a total of 1838 nonsynonymous mutations previously discovered in protein-coding regions of these samples, we identified 3 general classes of mutations that could generate tumor-specific neoantigens. The most abundant class consisted of missense mutations that cause single amino acid changes and comprised 90% of somatic mutations per CLL, with 69% of 91 cases having between 10 and 25 missense mutations per sample (Figure 2A). The other 2 classes of mutations, frameshifts and splice-site mutations, have the potential to generate longer stretches of novel amino acid sequences entirely specific to the tumor (neo-open reading frames [neoORFs]), with a higher number of neoantigen peptides per alteration (compared with missense mutations). However, neoORF-generating mutations were ∼10-fold less abundant than missense mutations in CLL (Figure 2A-C). Given the prevalence of missense mutations, we focused our initial studies on the analysis of neoantigens generated from this mutation class.

T-cell receptor (TCR) recognition of peptide epitopes requires the presentation of peptides by HLA molecules on the surface of APCs. We applied NetMHCpan prospectively to 31 of 91 CLL cases for which HLA typing information was available²⁶  to predict the binding affinities of peptides generated by somatic mutation to each patient’s MHC class I alleles, because this algorithm consistently performs with high sensitivity and specificity across HLA alleles.^21,35,36  Based on standard criteria in the field, we considered peptides with IC₅₀ < 150 nM as strong binders, IC₅₀ of 150 to 500 nM as intermediate to weak binders, and IC₅₀ >500 nM as nonbinders.²⁹  For the 31 cases, we found a median of 10 strong (range, 2-40) and 12 intermediate to weak binding peptides (range, 2-41) per case. In total, a median of 22 (range, 6-81) peptides per case was predicted with IC₅₀ < 500 nM (Figure 3A; supplemental Table 1).

To experimentally validate the predicted IC₅₀ nanomolar scores, we performed a competitive MHC I allele binding assay (supplemental Table 2)²⁸  and focused on class I HLA-A and -B alleles. To this end, we synthesized 102 unique mutated 9- or 10-mer peptides with predicted IC₅₀ < 500 nM (representing a total of 112 epitopes, as 10 peptides were predicted to bind to multiple alleles within the same patient), identified from 4 CLL cases (patients 1-4). Experimental binding (defined as IC₅₀ <500 nM) was confirmed in 76.5% and 36% of the 112 peptides predicted with IC₅₀ of < 150 or 150 to 500 nM, respectively (Figure 3B). In total, ∼55% (61 of 112) of predicted peptides were experimentally validated as binders to personal HLA alleles. Eighty percent of the 347 mutated genes (or 79% of the 180 mutations with predicted HLA binding) were expressed at medium or high expression levels (Figure 3C).

As proof of concept that an immune response against the predicted mutated peptides can develop in humans, we studied 2 patients who underwent reduced-intensity allogeneic HSCT in CLL and had achieved continuous remission for >4 years (supplemental Table 3). We reasoned that reconstitution of T cells from a healthy donor following HSCT would overcome endogenous immune defects of the host and allow priming against leukemia cells in the host in vivo. Posttransplant T cells were collected 7 (patient 1) and 4 years (patient 2) from the time of transplant.

For patient 1, we identified 25 missense mutations by WES. In total, 30 candidate epitopes (from 25 unique peptides, with 5 peptides predicted to bind to multiple HLA alleles) from 13 mutations were predicted to bind to personal HLA (13 peptides with IC₅₀ < 150; 17 peptides with IC₅₀ of 150-500 nM), with empirical confirmation of HLA binding for 13 candidate epitopes (10 unique peptides) derived from 8 mutations (Figure 4A). We organized all 30 predicted HLA binding peptides into 5 pools (6 peptides/pool) for T-cell priming studies (supplemental Table 4). To test T cells for neoantigen reactivity, we first expanded them using autologous APCs pulsed with candidate neoantigen peptide pools (once per week × 4). As shown in Figure 4B, reactivity was detected against pool 2 by IFN-γ ELISPOT, but not against an irrelevant HTLV1-Tax peptide. Deconvolution of the pool revealed that the mutated (mut) ALMS1 and C6ORF89 peptides within pool 2 were immunogenic (Figure 4C). ALMS1 plays a role in ciliary function, cellular quiescence, and intracellular transport,^37,38  whereas C6ORF89 encodes a protein that interacts with bombesin receptor subtype 3 (involved in cell cycle progression and wound repair of bronchial epithelial cells).^39,40 

In patient 2, we tested whether personal neoantigens could contribute to memory T-cell responses in the setting of long-lived remission. From this individual, we identified 26 missense mutations. In total, 37 candidate epitopes (from 36 unique peptides; 1 peptide was predicted to bind to 2 different HLA alleles) from 16 mutations were predicted to bind to personal HLA alleles, of which 18 peptides (17 unique) from 12 mutations could be experimentally validated (15 with IC₅₀ < 150; 3 with IC₅₀ of 150-500 nM; Figure 5A). We studied all 18 experimentally validated HLA-binding peptides, and T-cell stimulations were performed using 3 pools of 6 peptides/pool (supplemental Methods; supplemental Table 5). We assessed memory responses by undertaking short-term stimulations of T cells in vitro (ie, 2 rounds of weekly stimulations of T cells against mutated peptide pool-pulsed autologous APCs),^27,30  and identified T cells reactive against pool 1 (Figure 5B). Deconvolution of the pool revealed mut-FNDC3B as the dominant immunogenic peptide within this pool (experimental IC₅₀ of mut- and wt-FNDC3B: 6.2 and 2.7 nM, respectively; Figure 5C). Presence of this population of neoepitope-reactive T cells was specific to patient 2 because a similar stimulation procedure applied to 3 unrelated HLA-A*02:01 healthy adult volunteers failed to generate detectable mut-FNDC3B peptide-specific T cells despite 4 rounds of weekly stimulations, although T-cell responses could be generated against the M1 (Flu peptide-GILGFVFTL) peptide (positive control) (supplemental Figure 1). The function of FNDC3B in blood malignancies is unclear, although down-regulation of its expression is known to up-regulate miR-143 expression, which differentiates prostate cancer stem cells and promotes prostate cancer metastasis.^40,41 

T-cell reactivity against mut-FNDC3B in patient 2 was polyfunctional (secreting IFN-γ, granulocyte macrophage–colony-stimulating factor [GM-CSF], and IL-2), highly avid, and specific to the mut-FNDC3B peptide but not its wild-type counterpart (Figure 5D). T-cell reactivity was abrogated by the presence of class I blocking antibody (W6/32), indicating that T-cell reactivity was class I restricted (Figure 5E, left). Moreover, the mut-FNDC3B peptide appeared to be naturally processed and presented because T-cell reactivity was detected against HLA-A2-expressing APCs that were transfected with a 300-bp minigene encompassing the region of gene mutation, but not the wild-type minigene or untransfected HLA-A2-expressing APCs (Figure 5E, right). Furthermore, mut-FNDC3B peptide-recognizing T cells from patient 2 were also reactive against autologous tumor cells, generating IFN-γ secretion at levels comparable to mutated peptide-pulsed targets (Figure 5F).

Using a mut-FNDC3B/A2⁺-specific tetramer, we detected a discrete population of mut-FNDC3B-reactive CD8⁺ T cells within pool 1-stimulated T cells (2.42% of the population) compared with control PBMCs from a healthy adult HLA-A2⁺ volunteer (0.38%) (Figure 5G). Gene expression analysis and quantitative polymerase chain reaction (qPCR) of FNDC3B in CLL cases (including patient 2) and resting and CD40L-activated CD19⁺ B cells from healthy adult volunteers revealed this gene to be relatively overexpressed in patient 2 (supplemental Figure 2).

To define the relative kinetics of mut-FNDC3B-specific T cells in relationship to post-HSCT course, patient 2 T cells isolated from different time points before and after HSCT were stimulated in the same experiment for only 2 weeks and then tested for IFN-γ reactivity on ELISPOT. As shown in Figure 6A (top and middle panels), mut-FNDC3B T cell responses were not detected before or up to 3 months following HSCT. Molecular remission was first achieved 4 months following HSCT, and mut-FNDC3B-specific T cells were then first detected 6 months following HSCT, coinciding the molecular remission. Antigen-specific reactivity subsequently waned (between 12 and 20 months after HSCT) but was again strongly detected at 32 months after HSCT. Based on molecular analysis of the TCR of the mut-FNDC3B-specific T cells, we identified Vβ11 as the predominant CDR3 Vβ subfamily used by the reactive T cells (supplemental Figure 3; supplemental Table 6). Using this molecular information, we developed a clone-specific nested PCR and observed that T cells with the same specificity for mut-FNDC3B were not detected in PBMCs (n = 3) and CD8⁺ T cells of normal healthy volunteers (supplemental Table 7), but could be detected with similar kinetics as detection of IFN-γ secretion following HSCT in the patient (Figure 6A, bottom panel).

Consistent with a phenotype of degranulation, we observed higher levels of surface CD107a expression on mut-FNDC3B tetramer-positive T cells at 6 (by 32%) and 32 months (by 16%) after transplant following exposure to autologous leukemia cells compared with exposure to donor-engrafted normal B cells (Figure 6B). By contrast, we noted the absence of CD107a expression in the tetramer-negative CD8⁺ T cells (supplemental Figure 4). These results confirm that CD107a-mediated degranulation was directed against a tumor neoepitope (mut-FNDC3B) and not an alloantigen. The total percentage of CD8⁺ T cells expressing CD107a was ∼5% higher following stimulation with patient 2 tumor cells than with donor-engrafted normal B cells (representing background reactivity) or with 3 other HLA-A*02:01-positive CLL cells (supplemental Figure 5). These data demonstrate that the cytolytic capacity of mut-FNDC3B T cells against autologous CLL was personal and preserved over time.

To examine how tumor type and mutation rate could impact the overall estimate of abundance of candidate neoantigens, we applied our pipeline to publicly available WES data from 13 malignancies, whose overall somatic mutation rates have been previously reported.³²  To do so, we further implemented a recently developed algorithm that enables accurate inference of HLA typing from WES data (supplemental Methods).⁴² 

We predicted neoantigen loads from missense and frameshift mutations across tumors, setting an IC₅₀ threshold of <500 nM. Commensurate with the high mutation rate of melanoma, we observed an ∼20-fold higher number of predicted neoantigens per melanoma case (488; range, 18-5811), compared with CLL (24; range, 2-124) (Figure 7; supplemental Table 8). Our analysis supports the idea that the median number of predicted neopeptides generated from missense and frameshift events per sample is proportional to the mutation rate.

Each individual tumor harbors a broad spectrum of shared and personal genetic alterations that continue to evolve in response to the environment and often lead to therapeutic resistance.¹⁰  Given the uniqueness and plasticity of tumors, an optimal therapy may need to be customized based on the exact mutations present in each tumor and may need to target multiple nodes to avoid resistance.^43-46  The immune system of each individual, with its vast repertoire of CTLs, possesses this potential to simultaneously target multiple, personalized mutations (neoantigens). In a seminal and elegant study of a long-term melanoma survivor, Lennerz et al found that CTLs targeting neoantigens are significantly more abundant and sustained than those against nonmutated overexpressed tumor antigens.¹⁶  Since then, many studies in human^18,36,47-50  and murine^51-53  solid tumors support the critical role of protective immunity targeting neoantigens specifically expressed on the surface of tumor cells. Leveraging massively parallel sequencing and algorithms that effectively predict HLA-binding peptides, we report herein a comprehensive strategy to systematically identify potential immunogenic neoantigens across cancers.

We applied our strategy to a unique group of CLL patients who developed clinically evident durable remission associated with antitumor immune responses following allo-HSCT. These graft-versus-leukemia responses have typically been attributed to allo-reactive immune responses targeting hematopoietic cells,⁵⁴  but recent studies by our group and others have demonstrated the existence of graft-versus-leukemia-associated CTLs with specificity for tumor rather than allo-antigens.^27,55,56  In 2 patients in clinical remission for >4 years, we now show that peripheral blood-derived T cells recognizing 3 predicted neoantigen peptides can be stimulated and observed. For 1 of these neoepitopes (mutated FNDC3B), identified following only 2 weeks of in vitro stimulation, these T cells are (1) stimulated by the mutated but not by the cognate native peptide (Figure 5D), (2) recognize autologous APCs transfected with a minigene encoding a portion of the FNDC3B gene including the mutation (Figure 5E), and (3) recognize autologous tumor cells and peptide-pulsed autologous B cells (Figure 5F). Clinically, the level of this T-cell population correlated with disease remission as measured both by ELISPOT analysis and qPCR of the TCR associated with this target (Figure 6A), and these T cells were induced to express CD107a, a marker of cytotoxic potential, following exposure to patient CLL cells (Figure 6B). All these features are consistent with the role of neoantigens in protective immunity in solid tumors as discussed above, but now are extended to a hematological malignancy with a low mutation rate. Our results and the results of others, together with our pipeline, provide a method for selecting neoantigens for future personalized vaccines broadly applicable across tumors.

More generally, we estimated the abundance of neoantigens across many tumors (and a broad array of HLA alleles) and found ∼1.5 HLA-binding peptides with IC₅₀ < 500 nM per point mutation and ∼4 binding peptides per frameshift mutation. As expected, the estimated rate of predicted HLA binding peptides mirrored the somatic mutation rate per tumor type (Figure 7), wherein melanoma has the potential to generate the highest number of neoantigens and hematological malignancies including CLL generate less abundant neoantigens.

We recently reported the retrospective application of our pipeline to published immunogenic tumor neoantigens (ie, in which CTLs reactive to the mutated peptide were observed in patients) demonstrating that the vast majority (97%) of functional neoantigens are predicted to bind HLA with IC₅₀ <500 nM (with ∼70% of wild-type counterpart epitopes predicted to bind at a similar affinity).³⁶  This test using a gold standard set of neoantigens confirms that our pipeline largely classifies true positives correctly. A prospective prediction of neoepitopes followed by functional validation showed that 6% (3/48) of our predicted epitopes were associated with neoantigen-specific T-cell responses in patients—comparable to the rate of 4.8% found recently for melanoma.⁴⁷  The low proportion does not necessarily imply low prediction accuracy for the algorithm. Rather, number of true neoantigens is greatly underestimated by our experiments because (1) allo-HSCT is a general cellular therapy likely to induce only a small number of neoantigen-specific T-cell memory clones; and (2) our T-cell expansion methods are not sensitive enough to detect naïve T cells that represent a much larger part of the repertoire but with much lower precursor frequencies. Beyond the issue of prediction accuracy, we have also not yet measured the frequency of CTLs that target neoORFs—a class of neoantigens that we expect to be more specific (for lack of a wild-type counterpart) and immunogenic (as a result of bypassing thymic tolerance). Future improvements in predictive algorithms, and eventually, development of direct physical methods for detecting HLA-binding peptides using mass spectrometry,^57-59  will make it possible to more effectively select neoantigens presented by tumor HLA proteins. Considering the limitations described here, we conclude that there will be many more neoantigens per tumor.

Given the large number of candidate neoantigens, are there additional considerations that could help select the most useful antigens for targeting tumors? First, is it important to have high RNA or protein expression for CTLs to detect HLA-peptide complexes? Although no empirical studies have tested this question in human trials, it appears that very low levels (ie, even a single peptide-HLA protein) may be sufficient for a cell to be targeted by a CTL,⁶⁰  suggesting that high expression may not be required for inclusion of a neoantigen in a vaccine. Second, although theory suggests that essential cancer genes (drivers) are less likely to develop resistance under immune pressure, the 3 neoantigens (mutated FND3CB, ALMS1, and C6ORF89) found in our study exhibit attributes of passenger mutations as they are not evolutionarily conserved among species, and the mutation site has not been previously reported in other cancers (supplemental Figures 6 and 7). We found that the 3 CLL neoantigens were clonal or near-clonal (data not shown).^25,61  We thus suggest that CTLs associated with clinical responses can target tumor-specific mutations that are present in the bulk of the cancer mass (whether recurrent or not).

It is becoming increasingly evident that targeting multiple personal tumor epitopes is likely a useful therapeutic approach. In a recent study of the B16 murine melanoma model, HLA-binding neoantigens were predicted based on tumor mutations. Mice that were immunized with the corresponding mutated peptides developed CTLs specific to the mutated but not wild-type peptide and controlled disease therapeutically and prophylactically.⁵¹  In addition, recent studies in mice showing immune editing and escape to dominant CTL responses support the notion of targeting multiple epitopes to avoid resistance.^53,62  Focused prospective trials on small patient cohorts should now be possible to design based on our pipeline for selecting neoantigens to directly test the hypothesis that neoantigens are true targets of rejection responses and, due to their specificity, can be targeted both efficiently and safely by personalized immunotherapy.

The authors thank all the members of the Broad Institute’s Biological Samples, Genetic Analysis, and Genome Sequencing Platforms, who made this work possible. The authors also thank the expert clinical care provided by the DFCI clinical transplant team and assistance from the DFCI Cell Manipulation Core Facility, Pasquarello Tissue Bank. The authors also thank Jaewon Choi and Jessica Wong for excellent technical assistance and Glenn Dranoff, Todd Carter, Ute Burkhardt, and Ursula Hainz for valuable discussions.

This research was supported in parts by National Institutes of Health, National Human Genome Research Institute grant U54HG003067, National Cancer Institute grant 1RO1CA155010-02, National Heart, Lung, and Blood Institute grant 5R01HL103532-03, the Blavatinik Family Foundation, and the Leukemia and Lymphoma Translational Research Program. C.J.W. is a recipient of an Innovative Research Grant for Stand-Up to Cancer/American Association of Cancer Research.

Contribution: M.R. directed the study design and performed experimental and data analysis with guidance from C.J.W. S.A.S., V.B., E.F.F., and D.D. developed the neoantigen discovery pipeline; J.R. provided clinical specimens for the study; E.C., W.Z., and D.B.K. contributed to the T-cell experiments; C.S., K.C., G.G., and S.G. coordinated the tumor sequencing and somatic mutation analysis; J.S. performed the experimental binding assays; K.S. and D.N. performed statistical analysis; M.R. wrote the manuscript; C.J.W., N.H., E.F.F., and E.S.L. edited the manuscript; and all authors discussed and interpreted results.

Conflict-of-interest disclosure: Patent applications have been filed on aspects of the work described in the paper entitled as follows: Compositions and Methods for Personalized Neoplasia Vaccines (N.H., E.F.F., and C.J.W.) and Methods for Identifying Tumor Specific Neo-Antigens (N.H. and C.J.W.) (PCT/US2011/036665). The remaining authors declare no competing financial interests.

Correspondence: Catherine J. Wu, Dana-Farber Cancer Institute, 450 Brookline Ave, Dana 540B, Boston, MA 02215; e-mail: cwu@partners.org.